Making cancer clinical trials more inclusive and representative

This is a research study testing a new process called DIVERSE that aims to make blood cancer clinical trials more inclusive and representative of all patients. The study invites both patients with a history of blood cancer and community members to join an advisory board, where they would receive training and then review clinical trials in development. By sharing your perspective as a patient or community member, you'd help researchers understand how to design better, more inclusive trials.

Many clinical trials don't include enough diverse patients, which means researchers may miss important information about how treatments work for different populations. This study exists to test whether involving patients and community members early in trial design can help create studies that are fairer and more representative of everyone who might benefit from new cancer treatments.